Phase 4 N=40 Fibrinolysis Before Cardiopulmonary Bypass?
Pathologic Fibrinolysis
Primary: Di-Dimer Increase Before Cardiopulmonary Bypass — 317; 266; 317; 291 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
Severe Acute Respiratory Syndrome · Respiratory Failure · Acute Respiratory Distress Syndrome
Primary: PaO2/FiO2 Change (Increase) From Pre-to-post Intervention — 16.9; 29.8 percent change
N/A N=51 Thromboelastography-derived Functional Fibrinogen Levels
Focus of Study · Coagulation Status of Cardiac Surgery Patient · Reducing Excess Blood Transfusion
Primary: Change in Thromboelastography-derived Functional Fibrinogen Level (FLEV) — -1.1 mg/dL
Phase 3 N=465 Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
COVID-19
Primary: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days. — 37; 52 Participants
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Phase 4 N=20 Transfusion of Pathogen Reduced Cryoprecipitated Fibrinogen to Expedite Product Availability in Perioperative Bleeding
Hypofibrinogenemia · Bleeding
Primary: Total Number of RBCs Used Over Admission — 5.8; 6.7 RBC Units
Phase 4 N=437 Fibrinogen in Haemorrhage of Delivery
Post-Partum Hemorrhage
Primary: Failure Rate of PPH Management — 75; 80; 92; 92 Participants — p=0.9563
Phase 4 N=5 Fibrinolytic Therapy Versus Medical Thoracoscopy
Pleural Diseases
Primary: Number of Hospital Days for Required to Treat Complicated Parapneumonic Effusions or Pleural Empyema. — 13; 18.5 days
Phase 4 N=32 Fibrinolysis Compared to Thoracoscopy for Pleural Infection
Pleural Infection · Empyema · Pleural Diseases
Primary: Duration of Hospital Stay After Intervention — 4; 2 days
Phase 4 N=27 Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Pleural Effusion
Primary: Chest X-ray Results on Day 3 After Pleurodesis — 5; 6; 5; 8 Participants — p=0.863
Phase 4 N=60 Fibrinogen Concentrate vs Cryoprecipitate
Congenital Heart Disease
Primary: Total Units of Intraoperative Allogenic Donor Transfusions (ADT) Administered During Procedure Through ICU Arrival. — 5; 4 ADT units
N/A N=72 Clinical Trial of Factor XIII (FXIII) Concentrate
Hemophilia · Factor XIII Deficiency
Primary: Response to Treatment of Bleeding Events Requiring Additional Factor XIII Infusions — 30; 1; 0; 3 Number of bleeds
N/A N=99 Platelet Function in Resuscitated Patients
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
N/A N=10 Treatment of Complicated Parapneumonic Effusion With Fibrinolytic Therapy Versus VATs Decortication
Parapneumonic Effusion · Empyema, Pleural · Coagulopathy
Primary: Hospital Length of Stay — 12.4; 8.4 days
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 4 N=86 The RAS, Fibrinolysis and Cardiopulmonary Bypass
Coronary Artery Disease · Angiotensin Converting Enzyme · Angiotensin Receptor Blockers
Primary: Tissue-type Plasminogen Activator (t-PA) Antigen Response — 14.36; 14.05; 11.97; 27.65 ng/mL — p=0.28
Phase 3 N=36 In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)
Hemostasis
Primary: Clot Degradation at 24 Hours Post-operatively — 0.65; 0.88; 0.78; 0.46 microns per hour
Phase 2 N=15 Human Fibrinogen - Pharmacokinetics
Fibrinogen Deficiency
Primary: Maximum Clot Firmness (MCF) — 0; 8.9 millimeters — p=<0.0001
Phase 2 N=174 A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion
Acute Peripheral Arterial Occlusion
Primary: The Proportion of Subjects With >50% Thrombolysis — 43.8; 47.4; 81.0; 47.4 percentage of participants
Phase 3 N=62 Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery
Cardiac Complication During Procedure
Primary: Cumulative Transfusion Units — 0; 0 Transfusion Units — p=.908
Early Phase 1 N=28 RAS and Coagulopathy in COVID19
COVID
Primary: Coagulopathy Associated With COVID-19 — -313; -129.5 ng/mL FEU
Phase 3 N=222 Adjusted Fibrinogen Replacement Strategy
Bleeding Disorder · Hypofibrinogenemia; Acquired
Primary: Intra-operative Blood Loss — 1380.7; 1660.13 mL — p=<0.001
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
Phase 2 N=141 The Fibrin Patch Soft Tissue Study
Hemostasis
Primary: Proportion of Subjects Achieving Hemostatic Success — 98.3; 53.3; 98.0 percentage of success
N/A N=103 Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
Liver Transplantation · Kidney Transplantation
Primary: Delayed Kidney Graft Function — 5; 7 Participants
Phase 2 N=22 Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital Afibrinogenemia
Congenital Afibrinogenemia
Primary: Area Under the Plasma Fibrinogen Concentration-time Curve (AUC) From Time Zero to 14 Days (AUC0-14days) of FIB Grifols Determined by Clauss Method, Dose Normalized to 70…
N/A N=28 Sepsis-Associated Purpura Fulminans International Registry - Europe
Sepsis
Primary: Mortality — 11 Participants
N/A N=114 Comparison of Rapid Thrombelastography and Conventional Coagulation Testing for Haemostatic Resuscitation in Trauma
Acute Coagulopathy
Primary: 28 Day In-hospital Mortality — 20; 11 participants — p=0.04
Phase 2 N=73 Fibrin Sealant Vascular Surgery Study
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Primary: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line. — 46.2; 62.5; 34.8; 30.8 percentage of participants
Phase 3 N=1,604 Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
Trauma Injury
Primary: Number of Participants With Mortality From Any Cause — 201; 192 Participants